MapLight Therapeutics Shares Fall 4.7% After Insider Selling
MapLight Therapeutics is a clinical-stage biotech firm that develops drugs for brain disorders. The firm’s stock price fell by 4.79% today, followed by news about its director selling $119,743.32 worth of shares. MapLight’s share price dipped to $17.69, marking a 1.17% decrease in January. MapLight Therapeutics went public in October 2025 with its IPO price … Read more



